DOCSLIB.ORG

Active Labelers Run Date : Feb 28, 2019

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Active Labelers Run Date : Feb 28, 2019 Labeler ID Labeler Name Contract Begin Date Contract End Date 00002 ELI LILLY AND COMPANY 07/01/1991 01/01/3000 00003 E.R. SQUIBB & SONS, LLC. 07/01/1991 01/01/3000 00004 HOFFMANN-LA ROCHE 01/01/1991 01/01/3000 00006 MERCK & CO., INC. 07/01/1991 01/01/3000 00007 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00008 WYETH LABORATORIES 01/01/1991 01/01/3000 00009 PHARMACIA AND UPJOHN COMPANY LLC 01/01/1991 01/01/3000 00013 PHARMACIA AND UPJOHN COMPANY LLC 01/01/1991 01/01/3000 00014 PFIZER, INC 01/01/1991 01/01/3000 00015 MEAD JOHNSON AND COMPANY 07/01/1991 01/01/3000 00023 ALLERGAN INC 07/01/1991 01/01/3000 00024 SANOFI-AVENTIS, US LLC 07/01/1991 01/01/3000 00025 GD. SEARLE LLC DIVISION OF PFIZER INC. 01/01/1991 01/01/3000 00026 BAYER HEALTHCARE LLC 01/01/1991 01/01/3000 00029 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00032 ABBVIE INC. 07/01/1991 01/01/3000 00037 MEDA PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00039 SANOFI-AVENTIS, US LLC 07/01/1991 01/01/3000 00046 WYETH PHARMACEUTICALS INC. 01/01/1991 01/01/3000 00049 ROERIG 01/01/1991 01/01/3000 00051 ABBVIE INC 10/01/1997 01/01/3000 00052 ORGANON USA INC. 07/01/1991 01/01/3000 00053 CSL BEHRING LLC 07/01/1991 01/01/3000 00054 WEST-WARD PHARMACEUTICALS CORP. 07/01/1991 01/01/3000 00056 BRISTOL-MYERS SQUIBB PHARMA CO. 07/01/1991 01/01/3000 00065 ALCON LABORATORIES, INC. 07/01/1991 01/01/3000 00066 AVENTIS PHARMACEUTICALS, INC. 07/01/1991 01/01/3000 00067 GSK CONSUMER HEALTH 07/01/1991 01/01/3000 00068 AVENTIS PHARMACEUTICALS 07/01/1991 01/01/3000 00069 PFIZER LABORATORIES DIV PFIZER INC 01/01/1991 01/01/3000 00070 AVENTIS PHARMACEUTCALS 01/01/1991 01/01/3000 00071 PARKE-DAVIS DIV OF PFIZER 01/01/1991 01/01/3000 00074 ABBVIE INC 07/01/1991 01/01/3000 00075 AVENTIS PHARMACEUTICALS, INC. 07/01/1991 01/01/3000 00078 NOVARTIS 07/01/1991 01/01/3000 00085 SCHERING CORPORATION 07/01/1991 01/01/3000 ©2019 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Feb 28, 2019 Labeler ID Labeler Name Contract Begin Date Contract End Date 00087 BRISTOL-MYERS SQUIBB COMPANY 07/01/1991 01/01/3000 00088 AVENTIS PHARMACEUTICALS 07/01/1991 01/01/3000 00091 UCB, INC 07/01/1991 01/01/3000 00093 TEVA PHARMACEUTICALS USA, INC. 07/01/1991 01/01/3000 00095 ECR PHARMACEUTICALS 10/01/1991 01/01/3000 00096 PERSON & COVEY, INC. 04/01/1999 01/01/3000 00113 L. PERRIGO COMPANY 04/30/2003 01/01/3000 00115 IMPAX GENERICS 07/01/1991 01/01/3000 00116 XTTRIUM LABORATORIES, INC. 08/17/2001 01/01/3000 00121 PHARMACEUTICAL ASSOCIATES, INC. 01/01/1991 01/01/3000 00131 UCB, INC. 07/01/1991 01/01/3000 00132 C B FLEET COMPANY INC 01/01/1991 01/01/3000 00135 GSK CONSUMER HEALTHCARE HOLDINGS (US)LL 07/01/1995 01/01/3000 00143 WEST-WARD PHARMACEUTICAL CORP 07/01/1991 01/01/3000 00145 STIEFEL LABORATORIES, INC, 01/01/1991 01/01/3000 00168 E FOUGERA AND CO. 07/01/1991 01/01/3000 00169 NOVO NORDISK, INC. 01/01/1992 01/01/3000 00172 IVAX PHARMACEUTICALS, INC. 07/01/1991 01/01/3000 00173 GLAXOSMITHKLINE 01/01/1991 01/01/3000 00178 MISSION PHARMACAL COMPANY 01/01/1991 01/01/3000 00182 GOLDLINE LABORATORIES, INC. 07/01/1991 01/01/3000 00185 EON LABS, INC. 07/01/1991 01/01/3000 00186 ASTRAZENECA PHARMACEUTICALS LP 07/01/1991 01/01/3000 00187 VALEANT PHARMACEUTICALS NORTH AMERICA 07/01/1991 01/01/3000 00192 BAYER CORPORATION PHARMACEUTICAL DIV. 01/01/1991 01/01/3000 00206 WYETH PHARMACEUTICALS LLC 01/01/1991 01/01/3000 00224 KONSYL PHARMACEUTICALS, INC. 01/01/1992 01/01/3000 00225 B. F. ASCHER AND COMPANY, INC. 07/01/1991 01/01/3000 00228 ACTAVIS ELIZABETH LLC 07/01/1991 01/01/3000 00245 UPSHER-SMITH LABORATORIES, INC. 01/01/1991 01/01/3000 00254 PAR PHARMACEUTTICAL INC. 09/28/2018 01/01/3000 00258 FOREST LABORATORIES INC 07/01/1991 01/01/3000 00259 MERZ PHARMACEUTICALS 07/01/1991 01/01/3000 00264 B. BRAUN MEDICAL INC. 07/01/1991 01/01/3000 00281 SAVAGE LABORATORIES 07/01/1991 01/01/3000 00299 GALDERMA LABORATORIES, L.P. 01/01/1991 01/01/3000 ©2019 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Feb 28, 2019 Labeler ID Labeler Name Contract Begin Date Contract End Date 00310 ASTRAZENECA PHARMACEUTICALS LP 07/01/1991 01/01/3000 00316 CROWN LABORATORIES, INC. 01/30/2018 01/01/3000 00327 GUARDIAN LABS DIV UNITED-GUARDIAN INC 07/01/1991 01/01/3000 00338 BAXTER HEALTHCARE CORPORATION 01/01/1991 01/01/3000 00378 MYLAN PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00406 SPEC GX, LLC 10/01/1991 01/01/3000 00407 GE HEALTHCARE, INC. 07/05/2011 01/01/3000 00409 HOSPIRA, INC. 10/28/2004 01/01/3000 00430 WARNER CHILCOTT (US) LLC 07/01/1998 01/01/3000 00456 FOREST LABORATORIES, INC. 07/01/1991 01/01/3000 00469 ASTELLAS PHARMA US, INC. 07/01/1991 01/01/3000 00472 ACTAVIS 07/01/1991 01/01/3000 00485 EDWARDS PHARMACEUTICALS, INC. 01/01/1991 01/01/3000 00486 BEACH PRODUCTS INC 01/01/1991 01/01/3000 00487 NEPHRON PHARMACEUTICALS CORPORATION 04/01/1992 01/01/3000 00517 AMERICAN REGENT, INC. 10/01/1991 01/01/3000 00527 LANNETT COMPANY, INC. 07/01/1994 01/01/3000 00536 RUGBY LABORATORIES 01/01/1991 01/01/3000 00548 AMPHASTAR PHARMACEUTICALS, INC. 10/22/2012 01/01/3000 00555 BARR LABORATORIES INC 07/01/1991 01/01/3000 00562 KEDRION MELVILLE, INC. 01/18/2013 01/01/3000 00574 PADDOCK LABORATORIES, INC. 01/01/1991 01/01/3000 00575 TEVA GLOBAL RESPIRATORY RESEARCH, LLC 10/01/1991 01/01/3000 00590 BRISTOL MYERS SQUIBB HOLDINGS PHARMA LT 07/01/1991 01/01/3000 00591 WATSON PHARMA, INC. 03/29/2001 01/01/3000 00597 BOEHRINGER INGELHEIM PHARMACEUTICALS 01/01/1991 01/01/3000 00603 PAR PHARMACEUTICAL 01/01/1991 01/01/3000 00641 WEST-WARD PHARMACEUTICAL 07/01/1991 01/01/3000 00642 EXELTIS USA, INC. 07/01/1991 01/01/3000 00662 PFIZER-ROERIG 01/01/1991 01/01/3000 00663 PFIZER, INC 01/01/1991 01/01/3000 00682 MARNEL PHARMACEUTICAL, INC. 01/01/1991 01/01/3000 00703 TEVA PARENTERAL MEDICINES INC 10/01/1992 01/01/3000 00713 G&W LABORATORIES, INC 01/01/1991 01/01/3000 00777 DISTA PRODUCTS CO DIV OF ELI LILLY & CO 07/01/1991 01/01/3000 00781 SANDOZ 07/01/1991 01/01/3000 ©2019 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Feb 28, 2019 Labeler ID Labeler Name Contract Begin Date Contract End Date 00813 PHARMICS INC. 07/01/1991 01/01/3000 00832 UPSHER-SMITH LABORATORIES, INC. 01/01/1991 01/01/3000 00884 PEDINOL PHARMACAL INC 07/01/1991 01/01/3000 00904 MAJOR PHARMACEUTICALS 01/01/1991 01/01/3000 00905 PFIZER, INC 01/01/1991 01/01/3000 00941 BAXTER HEALTHCARE CORPORATION 04/01/2010 01/01/3000 00944 BAXALTA US INC 01/01/1991 01/01/3000 00955 SANOFI-SYNTHELABO INC. 07/01/1996 01/01/3000 00990 ICU MEDICAL INC. 07/12/2018 01/01/3000 00995 PFIZER, INC 01/01/1991 01/01/3000 00998 ALCON LABORATORIES, INC. 07/01/1991 01/01/3000 10019 BAXTER HEALTHCARE CORPORATION 06/28/2001 01/01/3000 10094 AQUESTIVE THERAPEUTICS, INC. 12/05/2018 01/01/3000 10122 CHIESI USA, INC. 04/26/2005 01/01/3000 10144 ACORDA THERAPEUTICS, INC. 05/27/2005 01/01/3000 10147 PATRIOT PHARMACEUTICALS, LLC. 01/13/2005 01/01/3000 10148 COTHERIX, INC. 09/06/2018 01/01/3000 10337 DOAK DERMATOLOGICS 04/16/2002 01/01/3000 10370 PAR PHARMACEUTICALS, INC. 05/14/2007 01/01/3000 10454 SOLSTICE NEUROSCIENCES, INC. 10/18/2005 01/01/3000 10511 PHOTOCURE, INC. 01/07/2013 01/01/3000 10542 HILLESTAD PHARMACEUTICALS 04/01/1994 01/01/3000 10572 AFFORDABLE PHARMACEUTICALS, LLC 11/01/2004 01/01/3000 10599 INTERSECT ENT, INC. 02/12/2018 01/01/3000 10631 RANBAXY LABORATORIES INCORPORATED 07/20/2005 01/01/3000 10702 KVK-TECH, INC. 10/10/2006 01/01/3000 10885 GALEN US INCORPORATED 11/22/2013 01/01/3000 10888 BANNER PHARMACAPS INC. 05/09/2012 01/01/3000 10922 INTENDIS, INC. 08/01/2005 01/01/3000 11042 MIDDLEBROOK PHARMACEUTICALS, INC. 08/22/2005 01/01/3000 11534 SUNRISE PHARMACEUTICAL, INC. 10/12/2015 01/01/3000 11980 ALLERGAN INC 07/01/1991 01/01/3000 11994 LANTHEUS MEDICAL IMAGING, INC. 10/06/2010 01/01/3000 12496 INDIVOR INC. 01/01/1994 01/01/3000 12830 R.A. MCNEIL COMPANY 01/01/1991 01/01/3000 13107 AUROBINDO PHARMA USA, INC. 06/02/2005 01/01/3000 ©2019 Magellan Health, Inc. All Rights Reserved. Terms of Use / Privacy Policy / Disclaimer / Nondiscrimination & Languages Active Labelers Run Date : Feb 28, 2019 Labeler ID Labeler Name Contract Begin Date Contract End Date 13310 AR SCIENTIFIC, INC.
Recommended publications
  • BIOWORLD TODAY Inquiry

    BIOWORLD TODAY Inquiry

    BIOWORLDTM TODAY THE DAILY BIOPHARMACEUTICAL NEWS SOURCE JUNE 30 , 2016 BIOTECH’S MOST RESPECTED NEWS SOURCE FOR MORE THAN 20 YEARS VOLUME 27, NO. 126 LIPID JAM NOT OVER EASILY STOPPED FOR FUTILITY Waffle house? FDA Galena Biopharma implodes as PRESENT review fidgets endpoint, puts cancer vaccine Neuvax future in doubt outcome details; By Jennifer Boggs, Managing Editor Esperion grilled on holdup With the bulk of Galena Biopharma Inc.’s value riding on cancer vaccine Neuvax By Randy Osborne, Staff Writer (nelipepimut-S), the firm’s shares predictably plunged to a new 52-week low Wednesday as an independent data monitoring committee (IDMC) recommended the Analysts had plenty of questions but PRESENT phase III study in breast cancer be stopped for futility following a planned Esperion Therapeutics Inc. offered few interim analysis. But it’s the troubling language in the IDMC’s letter, suggesting the answers regarding the FDA’s stalling on placebo arm might actually have bested the treatment arm, that could signal the end oral, once-daily bempedoic acid (ETC- of the road for Neuvax. 1002) for lipid lowering, after the agency See Galena, page 3 See Esperion, page 4 CHINA DEALS AND M&A IN THE CLINIC Pfizer invests in Asia Merck strikes cancer SUPER ‘NOVA’ with $350M biotech vaccines deal with Tesaro shares blast plant in Hangzhou Moderna, delivering off as niraparib hits By Haky Moon, Staff Writer $200M up front PFS in ovarian cancer HONG KONG – China’s economy may By Michael Fitzhugh, Staff Writer By Marie Powers, News Editor be slowing down, but multinationals Findings from the phase III NOVA trial are positioning themselves to leverage Cancer vaccines tailored to fit tumor- specific profiles are at the heart of a new of niraparib in women with recurrent it as best they can while navigating a ovarian cancer blasted shares of still-complex regulatory environment.
  • Infectious Diseases

    Infectious Diseases

    2013 MEDICINES IN DEVELOPMENT REPORT Infectious Diseases A Report on Diseases Caused by Bacteria, Viruses, Fungi and Parasites PRESENTED BY AMERICA’S BIOPHARMACEUTICAL RESEARCH COMPANIES Biopharmaceutical Research Evolves Against Infectious Diseases with Nearly 400 Medicines and Vaccines in Testing Throughout history, infectious diseases hepatitis C that inhibits the enzyme have taken a devastating toll on the lives essential for viral replication. and well-being of people around the • An anti-malarial drug that has shown Medicines in Development world. Caused when pathogens such activity against Plasmodium falci- For Infectious Diseases as bacteria or viruses enter a body and parum malaria which is resistant to multiply, infectious diseases were the current treatments. Application leading cause of death in the United Submitted States until the 1920s. Today, vaccines • A potential new antibiotic to treat methicillin-resistant Staphylococcus Phase III and infectious disease treatments have proven to be effective treatments in aureus (MRSA). Phase II many cases, but infectious diseases still • A novel treatment that works by Phase I pose a very serious threat to patients. blocking the ability of the smallpox Recently, some infectious pathogens, virus to spread to other cells, thus 226 such as pseudomonas bacteria, have preventing it from causing disease. become resistant to available treatments. Infectious diseases may never be fully Diseases once considered conquered, eradicated. However, new knowledge, such as tuberculosis, have reemerged new technologies, and the continuing as a growing health threat. commitment of America’s biopharma- America’s biopharmaceutical research ceutical research companies can help companies are developing 394 medicines meet the continuing—and ever-changing and vaccines to combat the many threats —threat from infectious diseases.
  • 05/01/02 Louisiana Medicaid Management

    05/01/02 Louisiana Medicaid Management

    APPENDIX C 05/01/02 LOUISIANA MEDICAID MANAGEMENT INFORMATION SYSTEM PAGE 1 DEPT OF HEALTH AND HOSPITALS - BUREAU OF HEALTH SERVICES FINANCING LOUISIANA MEDICAID PHARMACY BENEFITS MANAGEMENT UNIT ONLY THESE COMPANIES PRODUCTS ARE COVERED AND ONLY THOSE DOSAGE FORMS LISTED IN APPENDIX A. MEDICAID DRUG FEDERAL REBATE PARTICIPATING PHARMACEUTICAL COMPANIES LABELER PHARMACEUTICAL COMPANY EFFECTIVE END DATE CODE DATE 00002 ELI LILLY & CO 04/01/91 00003 E.R.SQUIBB & SONS,INC 04/01/91 00004 HOFFMAN-LA ROCHE,INC 04/01/91 00005 LEDERLE LABORATORIES AMERICAN CYANAMID 04/01/91 00006 MERCK SHARP & DOHME 04/01/91 00007 SMITHKLINE BEECHAM CORPORATION 04/01/91 00008 WYETH LABORATORIES 04/01/91 00009 THE UPJOHN COMPANY 04/01/91 00011 BECTON DICKINSON MICROBIOLOGY SYSTEMS 10/01/91 07/01/98 00013 ADRIA LABORATORIES DIV.OF ERBAMONT,INC 04/01/91 00014 G.D.SEARLE & CO 04/01/91 01/01/01 00015 MEAD JOHNSON & COMPANY 04/01/91 00016 KABI PHARMACIA 04/01/91 00021 REED & CARNRICK 10/01/96 01/01/97 00023 ALLERGAN,INC 04/01/91 00024 WINTHROP PHARMACEUTICALS 04/01/91 00025 G.D.SEARLE & CO 04/01/91 00026 MILES INC.,PHARMACEUTICAL DIVISION 04/01/91 00028 GEIGY PHARMACEUTICALS 04/01/91 00029 SMITHKLINE BEECHAM CORPORATION 04/01/91 00031 ROBINS,A.H. 04/01/91 00032 SOLVAY PHARMACEUTICALS 04/01/91 00033 SYNTEX 04/01/91 00034 THE PURDUE FREDERICK COMPANY 04/01/91 00037 CARTER-WALLACE,INC 04/01/91 00038 STUART PHARMACEUTICALS,ICI AMERICAS INC 04/01/91 07/01/01 00039 HOECHST-ROUSSEL PHARMACEUTICALS INC 04/01/91 00043 SANDOZ CONSUMER CORPORATION 04/01/91 00044 KNOLL PHARMACEUTICALS
  • NASDAQ Stock Market

    NASDAQ Stock Market

    Nasdaq Stock Market Friday, December 28, 2018 Name Symbol Close 1st Constitution Bancorp FCCY 19.75 1st Source SRCE 40.25 2U TWOU 48.31 21st Century Fox Cl A FOXA 47.97 21st Century Fox Cl B FOX 47.62 21Vianet Group ADR VNET 8.63 51job ADR JOBS 61.7 111 ADR YI 6.05 360 Finance ADR QFIN 15.74 1347 Property Insurance Holdings PIH 4.05 1-800-FLOWERS.COM Cl A FLWS 11.92 AAON AAON 34.85 Abiomed ABMD 318.17 Acacia Communications ACIA 37.69 Acacia Research - Acacia ACTG 3 Technologies Acadia Healthcare ACHC 25.56 ACADIA Pharmaceuticals ACAD 15.65 Acceleron Pharma XLRN 44.13 Access National ANCX 21.31 Accuray ARAY 3.45 AcelRx Pharmaceuticals ACRX 2.34 Aceto ACET 0.82 Achaogen AKAO 1.31 Achillion Pharmaceuticals ACHN 1.48 AC Immune ACIU 9.78 ACI Worldwide ACIW 27.25 Aclaris Therapeutics ACRS 7.31 ACM Research Cl A ACMR 10.47 Acorda Therapeutics ACOR 14.98 Activision Blizzard ATVI 46.8 Adamas Pharmaceuticals ADMS 8.45 Adaptimmune Therapeutics ADR ADAP 5.15 Addus HomeCare ADUS 67.27 ADDvantage Technologies Group AEY 1.43 Adobe ADBE 223.13 Adtran ADTN 10.82 Aduro Biotech ADRO 2.65 Advanced Emissions Solutions ADES 10.07 Advanced Energy Industries AEIS 42.71 Advanced Micro Devices AMD 17.82 Advaxis ADXS 0.19 Adverum Biotechnologies ADVM 3.2 Aegion AEGN 16.24 Aeglea BioTherapeutics AGLE 7.67 Aemetis AMTX 0.57 Aerie Pharmaceuticals AERI 35.52 AeroVironment AVAV 67.57 Aevi Genomic Medicine GNMX 0.67 Affimed AFMD 3.11 Agile Therapeutics AGRX 0.61 Agilysys AGYS 14.59 Agios Pharmaceuticals AGIO 45.3 AGNC Investment AGNC 17.73 AgroFresh Solutions AGFS 3.85
  • Market Cap Close ADV

    Market Cap Close ADV

    Market Cap Close ADV 1598 67th Pctl $745,214,477.91 $23.96 225,966.94 801 33rd Pctl $199,581,478.89 $10.09 53,054.83 2399 Listing_ Revised Ticker_Symbol Security_Name Exchange Effective_Date Mkt Cap Close ADV Stratum Stratum AAC AAC Holdings, Inc. N 20160906 M M M M-M-M M-M-M Altisource Asset Management AAMC Corp A 20160906 L M L L-M-L L-M-L AAN Aarons Inc N 20160906 H H H H-H-H H-H-H AAV Advantage Oil & Gas Ltd N 20160906 H L M H-L-M H-M-M AB Alliance Bernstein Holding L P N 20160906 H M M H-M-M H-M-M ABG Asbury Automotive Group Inc N 20160906 H H H H-H-H H-H-H ABM ABM Industries Inc. N 20160906 H H H H-H-H H-H-H AC Associated Capital Group, Inc. N 20160906 H H L H-H-L H-H-L ACCO ACCO Brand Corp. N 20160906 H L H H-L-H H-L-H ACU Acme United A 20160906 L M L L-M-L L-M-L ACY AeroCentury Corp A 20160906 L L L L-L-L L-L-L ADK Adcare Health System A 20160906 L L L L-L-L L-L-L ADPT Adeptus Health Inc. N 20160906 M H H M-H-H M-H-H AE Adams Res Energy Inc A 20160906 L H L L-H-L L-H-L American Equity Inv Life Hldg AEL Co N 20160906 H M H H-M-H H-M-H AF Astoria Financial Corporation N 20160906 H M H H-M-H H-M-H AGM Fed Agricul Mtg Clc Non Voting N 20160906 M H M M-H-M M-H-M AGM A Fed Agricultural Mtg Cla Voting N 20160906 L H L L-H-L L-H-L AGRO Adecoagro S A N 20160906 H L H H-L-H H-L-H AGX Argan Inc N 20160906 M H M M-H-M M-H-M AHC A H Belo Corp N 20160906 L L L L-L-L L-L-L ASPEN Insurance Holding AHL Limited N 20160906 H H H H-H-H H-H-H AHS AMN Healthcare Services Inc.
  • Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote

    Monday, April 22 Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Merck KLOX Technologies Immune Design Leading Biote

    As of 4/23/2013 Schedule subject to change Monday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room April 22 Merck KLOX Technologies Immune Design 1:00 PM Leading Biotech/Big Pharma Medical Devices Vaccines Eli Lilly NewSouth Innovations Syntiron 1:15 PM Leading Biotech/Big Pharma University/Academia Vaccines Amgen Radius Health BioCrea 1:30 PM Leading Biotech/Big Pharma Musculoskeletal Neurology/CNS Nat. Inst. of Neurological Dis. & Stroke Cytokinetics Xenon Pharmaceuticals 1:45 PM Neurology/CNS Musculoskeletal Neurology/CNS Curis OrgaNext Research BV Trigemina 2:00 PM Oncology Regenerative Medicine Neurology/CNS Verastem Flexion Therapeutics Neurocrine Biosciences 2:15 PM Oncology Musculoskeletal Hormone Therapy/CNS Michael J. Fox Foundation Antisense Pharma GmbH Versartis 2:30 PM Non-profit/Patient Advocacy Oncology Hormone Therapy Takeda Pharmaceutical Company TBD KODE Biotech 2:45 PM Leading Biotech/Big Pharma Drug Delivery Resverlogix Corp. Advaxis Q Chip 3:00 PM Cardiovascular Disease Oncology Drug Delivery Grünenthal GmbH Array BioPharma 3:15 PM Neurology/CNS Oncology/Drug Discovery Discovery Labs Mersana Therapeutics 3:30 PM Drug Delivery/Pulmonary Oncology Bayer HealthCare Igenica 3:45 PM Leading Biotech/Big Pharma Oncology Presentations are open to all Convention attendees and are located outside the main entrance of the BIO Business Forum As of 4/23/2013 - Schedule subject to change Tuesday, Chicago Bears Room Chicago Bulls Room Chicago Cubs Room Chicago Blackhawks Room April 23 Pfizer 8:00 AM Leading Biotech/Big Pharma
  • Ipo Analysis

    Ipo Analysis

    IPO ANALYSIS Snap Research on potential upcoming IPOs from Hamilton Lane Bitcoin Investment Trust selected candidate companies. Visterra Braeburn Pharmaceuticals December, 2016 VentureDeal Snap Files S-1 Registration For $3 Billion IPO Quick Take Camera company Snap Inc. (Pending:SNAP) has filed its initial S-1 registration for a $3 billion IPO at an undisclosed valuation. Snap views the camera as the primary use of the mobile device and seeks to monetize its user base primarily through advertising. The company has a short history of rapidly growing revenues, which exceeded $400 million in 2016. Company Venice-based Snap was founded in 2012 by current CEO Evan Spiegel and current CTO Robert Murphy to initially provide users with a smartphone app that enabled them to post pictures that were automatically deleted after a brief time period. The company has since expanded its scope to include chat, video, media that does not become automatically deleted, and a camera integrated into sunglasses. Below is a brief company video on its recently introduced Spectacles product: (Source: Snap YouTube) Snap has raised in excess of $2.6 billion in several private financing rounds from numerous investors including top tier venture capital firms, corporate investors, private equity firms and government-owned investment enterprises. The company claims that 158 million people use its flagship Snapchat each day, creating over 2.5 billion 'Snaps'. Market and Competition Snap operates a largely advertising-driven business model, although it does sell its Spectacles product for $129 each. It seeks to provide advertisers with access to its user base, which has typically centered around a younger demographic, between the ages of 14-30.
  • Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    Medicaid System (Mmis) Illinois Department of Run Date: 08/08/2015 Provider Subsystem Healthcare and Family Services Run Time: 21:25:58 Report Id 2794D052 Page: 01

    MEDICAID SYSTEM (MMIS) ILLINOIS DEPARTMENT OF RUN DATE: 08/08/2015 PROVIDER SUBSYSTEM HEALTHCARE AND FAMILY SERVICES RUN TIME: 21:25:58 REPORT ID 2794D052 PAGE: 01 ALPHA COMPLETE LIST OF PHARMACEUTICAL LABELERS WITH SIGNED REBATE AGREEMENTS IN EFFECT AS OF 10/01/2015 NDC NDC PREFIX LABELER NAME PREFIX LABELER NAME 68782 (OSI) EYETECH 65162 AMNEAL PHARMACEUTICALS LLC 00074 ABBOTT LABORATORIES 69238 AMNEAL PHARMACEUTICALS, LLC 68817 ABRAXIS BIOSCIENCE, LLC 53150 AMNEAL-AGILA, LLC 16729 ACCORD HEALTHCARE INCORPORATED 00548 AMPHASTAR PHARMACEUTICALS, INC. 42192 ACELLA PHARMACEUTICALS, LLC 66780 AMYLIN PHARMACEUTICALS, INC. 10144 ACORDA THERAPEUTICS, INC. 55724 ANACOR PHARMACEUTICALS 00472 ACTAVIS 10370 ANCHEN PHARMACEUTICALS, INC. 00228 ACTAVIS ELIZABETH LLC 62559 ANIP ACQUISITION COMPANY 45963 ACTAVIS INC. 54436 ANTARES PHARMA, INC. 46987 ACTAVIS KADIAN LLC 52609 APO-PHARMA USA, INC. 49687 ACTAVIS KADIAN LLC 60505 APOTEX CORP. 14550 ACTAVIS PHARMA MFGING PRIVATE LIMITED 63323 APP PHARMACEUTICALS, LLC. 67767 ACTAVIS SOUTH ATLANTIC 42865 APTALIS PHARMA US, INC 66215 ACTELION PHARMACEUTICALS U.S., INC. 58914 APTALIS PHARMA US, INC. 52244 ACTIENT PHARMACEUTICALS 13310 AR SCIENTIFIC, INC. 75989 ACTON PHARMACEUTICALS 08221 ARBOR PHARM IRELAND LIMITED 76431 AEGERION PHARMACEUTICALS, INC. 60631 ARBOR PHARMACEUTICALS IRELAND LIMITED 50102 AFAXYS, INC. 24338 ARBOR PHARMACEUTICALS, INC. 10572 AFFORDABLE PHARMACEUTICALS, LLC 59923 AREVA PHARMACEUTICALS 27241 AJANTA PHARMA LIMITED 76189 ARIAD PHARMACEUTICALS, INC. 17478 AKORN INC 24486 ARISTOS PHARMACEUTICALS, INC. 24090 AKRIMAX PHARMACEUTICALS LLC 67877 ASCEND LABORATORIES, L.L.C. 68220 ALAVEN PHARMACEUTICAL, LLC 76388 ASPEN GLOBAL INC. 00065 ALCON LABORATORIES, INC. 51248 ASTELLAS 00998 ALCON LABORATORIES, INC. 00469 ASTELLAS PHARMA US, INC. 25682 ALEXION PHARMACEUTICALS 00186 ASTRAZENECA LP 68611 ALIMERA SCIENCES, INC.
  • Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______

    Galena Biopharma, Inc. (Exact Name of Registrant As Specified in Its Charter) ______

    ANNUAL REPORT 201 OUR MISSION GALENA BIOPHARMA DEVELOPS AND COMMERCIALIZES INNOVATIVE, TARGETED ONCOLOGY TREATMENTS THAT ADDRESS MAJOR UNMET MEDICAL NEEDS TO ADVANCE CANCER CARE. MANAGEMENT TEAM Mark J. Ahn, Ph.D., President & Chief Executive Officer Remy Bernarda, Vice President, Marketing & Communications Gavin Choy, Pharm.D., Senior Vice President, Clinical Operations & Cinical Science Ryan Dunlap, CPA, Vice President, Chief Financial Officer Brian Hamilton, M.D., Ph.D., Executive Vice President & Chief Medical Officer Robert Laliberte, MS, Vice President, Clinical Operations & Clinical Science Christopher Lento, Vice President, Sales & Commercial Operations Hana B. Moran, Ph.D., Senior Vice President, Regulatory & Compliance Patricia Murphy, Vice President, Regulatory Affairs & Compliance Mark W. Schwartz, Ph.D., Executive Vice President & Chief Operating Officer SCIENTIFIC ADVISORY BOARD COL George Peoples, M.D., F.A.C.S., Chief, Surgical Oncology, Brooke Army Medical Center; Director and Principal Investigator, Cancer Vaccine Development Program, San Antonio Military Medical Center Hope S. Rugo, M.D., Clinical Professor of Medicine, Division of Hematology and Oncology at the University of California San Francisco Helen Diller Family Comprehensive Cancer Care Center Robert Figlin, M.D., F.A.C.P., Dr. Figlin is a fellow of the American College of Physicians and the International Society for Biologic Therapy as well as a member of the American Society of Clinical Oncology, the American Association for Cancer Research, and the American Urological Association. Dr. Gabriel N. Hortobagyi, M.D., F.A.C.P., is a Professor of Medicine and Chairman of the Department of Breast Medical Oncology and holds the Nellie B. Connally Chair in Breast Cancer Research at the University of Texas MD Anderson Cancer Center (MDACC).
  • Fidelity® Total Market Index Fund

    Fidelity® Total Market Index Fund

    Quarterly Holdings Report for Fidelity® Total Market Index Fund May 31, 2021 STI-QTLY-0721 1.816022.116 Schedule of Investments May 31, 2021 (Unaudited) Showing Percentage of Net Assets Common Stocks – 99.3% Shares Value Shares Value COMMUNICATION SERVICES – 10.1% World Wrestling Entertainment, Inc. Class A (b) 76,178 $ 4,253,780 Diversified Telecommunication Services – 1.1% Zynga, Inc. (a) 1,573,367 17,055,298 Alaska Communication Systems Group, Inc. 95,774 $ 317,970 1,211,987,366 Anterix, Inc. (a) (b) 16,962 838,941 Interactive Media & Services – 5.6% AT&T, Inc. 11,060,871 325,521,434 Alphabet, Inc.: ATN International, Inc. 17,036 805,292 Class A (a) 466,301 1,099,001,512 Bandwidth, Inc. (a) (b) 34,033 4,025,764 Class C (a) 446,972 1,077,899,796 Cincinnati Bell, Inc. (a) 84,225 1,297,065 ANGI Homeservices, Inc. Class A (a) 120,975 1,715,426 Cogent Communications Group, Inc. (b) 66,520 5,028,912 Autoweb, Inc. (a) (b) 6,653 19,028 Consolidated Communications Holdings, Inc. (a) 110,609 1,035,300 Bumble, Inc. 77,109 3,679,641 Globalstar, Inc. (a) (b) 1,067,098 1,707,357 CarGurus, Inc. Class A (a) 136,717 3,858,154 IDT Corp. Class B (a) (b) 31,682 914,343 Cars.com, Inc. (a) 110,752 1,618,087 Iridium Communications, Inc. (a) 186,035 7,108,397 DHI Group, Inc. (a) (b) 99,689 319,005 Liberty Global PLC: Eventbrite, Inc. (a) 114,588 2,326,136 Class A (a) 196,087 5,355,136 EverQuote, Inc.
  • References Used in Algorithms for the Treatment of Persons with Crohn’S Disease

    References Used in Algorithms for the Treatment of Persons with Crohn’S Disease

    REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH CROHN’S DISEASE 1. AA Pharma Inc: Winpred (prednisone). In: CA Product Monograph. Vaughan, ON; 2018. 2. AbbVie Corporation: Humira (adalimumab). In: CA Product Monograph. St Laurent, QC; 2019. 3. AbbVie Inc: Humira (adalimumab). In: US Product Monograph. North Chicago, IL; 2020. 4. Amgen Canada Inc: Avsola (infliximab). In: CA Product Monograph. Mississauga, ON; 2020. 5. Amgen Inc: Amjevita (adalimumab-atto). In: US Product Monograph. Thousand Oaks, CA; 2019. 6. Amgen Inc: Avsola (infliximab-axxq). In: US Product Monograph. Thousand Oaks, CA; 2019. 7. Antares Pharma Inc: Methotrexate. In: FDA Product Monograph. Ewing, NJ; 2019. 8. Apotex Inc: Methotrexate. In: CA Product Monograph. Toronto, ON; 2019. 9. Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, Kito K, Sugimoto M, Andoh A: NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease. Journal of gastroenterology 2016, 51(1):22-29. 10. Aspen Pharmacare Canada Inc: Imuran (azathioprine). In: CA Product Monograph. Oakville, ON; 2019. 11. Biogen Canada Inc: Tysabri (natalizumab). In: CA Product Monograph. Mississauga, ON; 2017. 12. Biogen Idec Inc: Tysabri (natalizumab). In: US Product Monograph. Cambridge, MA; 2019. 13. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ et al: Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clinical pharmacology and therapeutics 2015, 98(1):19-24. 14. Boehringer Ingelheim Pharmaceuticals Inc: Cyltezo (adalimumab-adbm). In: US Product Monograph. Ridgefield, CT; 2019.
  • P39262 Alimera Sciences, Inc. Nps 2020 V1

    P39262 Alimera Sciences, Inc. Nps 2020 V1

    Alimera Sciences, Inc. 6120 Windward Parkway, Suite 290 Alpharetta, Georgia 30005 NOTICE OF ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JUNE 18, 2020 To the Stockholders of Alimera Sciences, Inc.: The annual meeting of stockholders (the “Annual Meeting”) of Alimera Sciences, Inc. (the “Company”) will be held exclusively online via the Internet on Thursday, June 18, 2020, at 9:30 a.m. Eastern Time. The purposes of the meeting are: 1. To elect three Class I directors (Proposal 1); 2. To ratify the appointment of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2020 (Proposal 2); 3. To approve, on an advisory basis, the compensation of our named executive officers (Proposal 3); and 4. To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof. Our board of directors (the “Board”) has fixed the close of business on April 20, 2020 as the record date (the “record date”) for determining holders of our common stock and preferred stock entitled to notice of, and to vote at, the Annual Meeting or any adjournments or postponements thereof. This year we are again using the Internet as our primary means of furnishing proxy materials to stockholders. Accordingly, most stockholders will not receive printed copies of our proxy materials. We are instead mailing a Notice of Internet Availability of Proxy Materials with instructions for accessing the proxy materials and voting via the Internet (the “Notice”). This delivery method allows us to conserve natural resources and reduce the cost of delivery while also meeting our obligations to you, our stockholders, to provide information relevant to your continued investment in the Company.